Clinical trial · Supplements / medicine · 30 Jul 2026
Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial)
Source: The Lancet Healthy Longevity
What the research found
Study (randomized). The DEMFOS trial in The Lancet Healthy Longevity assigned 114 older adults with obesity (mean age 72.8; mostly men) to intensive diet-and-exercise plus metformin, intensive lifestyle plus placebo, or healthy-lifestyle education plus metformin. At 6 months, physical-performance-test gains were similar for intensive lifestyle with metformin versus placebo (mean difference 0.1 points, 95% CI −1.2 to 1.4). Lifestyle plus metformin beat education plus metformin by 2.5 points. Metformin did not add function on top of diet and exercise. Metformin remains a prescription diabetes medicine, not a longevity supplement. Off-label aging use is clinician-only. Not medical advice.
Evidence level: Clinical trial. This is among the stronger kinds of evidence, but one study rarely settles a question.
Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34